Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with or without Tremelimumab vs SoC in first-line advanced NSCLC (MYSTIC)
NCT02453282Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2015
- Primary completion
- Oct 2018
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 17
01
Overview
A Phase 3 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Jul 2015; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02453282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02453282.